Therapeutic potential of integrins in diabetic retinopathy

doi:10.4239/wjd.v16.i5.101509

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (24)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-1)

Sum=23

May 15, 2025 (publication date) through Apr 25, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Diabetes. May 15, 2025; 16(5): 101509
Published online May 15, 2025. doi: 10.4239/wjd.v16.i5.101509

Open in New Tab Full Size Figure Download Figure

Figure 1 Schematic illustration of integrin conformations. A: Bent-closed, inactive; B: Extended-closed, transition between inactive and active; integrins are extended but the ligand-binding site is not exposed; C: Extended-open, active; integrins are fully extended and the ligand-binding site is exposed. EGF: Epidermal growth factor; PSI: Plexin-semaphorin-integrin. Created by figdraw.com (Supplementary material).

Citation: He LM, Borjigin S, Chen XQ, Yan ZL, Wang MJ. Therapeutic potential of integrins in diabetic retinopathy. World J Diabetes 2025; 16(5): 101509
URL: https://www.wjgnet.com/1948-9358/full/v16/i5/101509.htm
DOI: https://dx.doi.org/10.4239/wjd.v16.i5.101509